Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Tsuji, B. T., Pogue, J. M., Zavascki, A. P., Paul, M., Daikos, G. L., Forrest, A., Giacobbe, D. R., Viscoli, C., Giamarellou, H., Karaiskos, I., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2209 · Cited by 949
Epidemiology of β-Lactamase-Producing Pathogens
Bush, K., & Bradford, P. A. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00047-19 · Cited by 938
Enterobacter Bacteremia: Clinical Features and Emergence of Antibiotic Resistance during Therapy
Chow, J. W., Fine, M. J., Shlaes, D. M., Quinn, J. P., Hooper, D. C., Johnson, M. P., Ramphal, R., Wagener, M. M., Miyashiro, D. K., & Yu, V. L. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-8-585 · Cited by 889
Combination Therapy for Treatment of Infections with Gram-Negative Bacteria
Tamma, P. D., Cosgrove, S. E., & Maragakis, L. L. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05041-11 · Cited by 836
Self-citationBassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., Lodise, T. P., Naas, T., Niki, Y., Paterson, D. L., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30796-9 · Cited by 828
Plasmid-Determined AmpC-Type β-Lactamases
Philippon, A., Arlet, G., & Jacoby, G. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.1-11.2002 · Cited by 816
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Association of adverse events with antibiotic use in hospitalized patients.
Tamma, P. D., Avdic, E., Li, D. X., Dzintars, K., & Cosgrove, S. E. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.1938 · Cited by 800
Self-citationExtended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection
Castanheira, M., Simner, P. J., & Bradford, P. A. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab092 · Cited by 796
Harris, P. N. A., Tambyah, P. A., Lye, D. C., Mo, Y., Lee, T. H., Yilmaz, M., Alenazi, T. H., Arabi, Y., Falcone, M., Bassetti, M., et al. (2018) · JAMA · doi:10.1001/jama.2018.12163 · Cited by 774
The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii
Turton, J. F., Ward, M. E., Woodford, N., Kaufmann, M. E., Pike, R., Livermore, D. M., & Pitt, T. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00195.x · Cited by 751
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Self-citationvan Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix783 · Cited by 655
Self-citationComparative Review of the Carbapenems
Zhanel, G. G., Wiebe, R., Dilay, L., Thomson, K., Rubinstein, E., Hoban, D. J., Noreddin, A. M., & Karlowsky, J. A. (2007) · Drugs · doi:10.2165/00003495-200767070-00006 · Cited by 652
Paul, M., Daikos, G. L., Durante-Mangoni, E., Yahav, D., Carmeli, Y., Benattar, Y. D., Skiada, A., Andini, R., Eliakim-Raz, N., Nutman, A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30099-9 · Cited by 623
Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy378 · Cited by 605
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02166-13 · Cited by 597
Meta-Analysis of Antibiotics and the Risk of Community-Associated Clostridium difficile Infection
Brown, K. A., Khanafer, N., Daneman, N., & Fisman, D. N. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02176-12 · Cited by 587
Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017.
Jernigan, J. A., Hatfield, K. M., Wolford, H., Nelson, R. E., Olubajo, B., Reddy, S. C., McCarthy, N., Paul, P., McDonald, L. C., Kallen, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914433 · Cited by 577
Stenotrophomonas maltophilia: an emerging opportunist human pathogen
Looney, W. J., Narita, M., & Mühlemann, K. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70083-0 · Cited by 550
Crossman, L. C., Gould, V. C., Dow, J. M., Vernikos, G. S., Okazaki, A., Sebaihia, M., Saunders, D., Arrowsmith, C., Carver, T., Peters, N., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-4-r74 · Cited by 544
Interplay between β-lactamases and new β-lactamase inhibitors
Bush, K., & Bradford, P. A. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0159-8 · Cited by 531
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Self-citationWunderink, R. G., Matsunaga, Y., Ariyasu, M., Clevenbergh, P., Echols, R., Kaye, K. S., Kollef, M., Menon, A., Pogue, J. M., Shorr, A. F., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30731-3 · Cited by 475
Wunderink, R. G., Giamarellos-Bourboulis, E. J., Rahav, G., Mathers, A. J., Bassetti, M., Vazquez, J., Cornely, O. A., Solomkin, J., Bhowmick, T., Bishara, J., et al. (2018) · Infectious Diseases and Therapy · doi:10.1007/s40121-018-0214-1 · Cited by 461
Self-citationTorres, A., Zhong, N., Pachl, J., Timsit, J.-F., Kollef, M., Chen, Z., Song, J., Taylor, D., Laud, P. J., Stone, G. G., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30747-8 · Cited by 441
Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1478 · Cited by 441
Self-citationSandri, A. M., Landersdorfer, C. B., Jacob, J., Boniatti, M. M., Dalarosa, M. G., Falci, D. R., Behle, T. F., Bordinhão, R. C., Wang, J., Forrest, A., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit334 · Cited by 430
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., Press, E. G., Kreiswirth, B. N., Clancy, C. J., & Nguyen, M. H. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw636 · Cited by 430
Self-citationMotsch, J., Murta de Oliveira, C., Stus, V., Köksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz530 · Cited by 422
Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., Yoon, M., Collins, S., Yuan, G., Barie, P. S., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ097 · Cited by 420
Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P., & Nagata, T. D. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30554-1 · Cited by 420
Chang, Y.-T., Lin, C.-Y., Chen, Y.-H., & Hsueh, P.-R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00893 · Cited by 419
Carmeli, Y., Armstrong, J., Laud, P. J., Newell, P., Stone, G., Wardman, A., & Gasink, L. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30004-4 · Cited by 417
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
Durante-Mangoni, E., Signoriello, G., Andini, R., Mattei, A., De Cristoforo, M., Murino, P., Bassetti, M., Malacarne, P., Petrosillo, N., Galdieri, N., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit253 · Cited by 405
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Rifampin: Mechanisms of Action and Resistance
Wehrli, W. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.supplement_3.s407 · Cited by 397
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Qureshi, Z. A., Hittle, L. E., O'Hara, J. A., Rivera, J. I., Syed, A., Shields, R. K., Pasculle, A. W., Ernst, R. K., & Doi, Y. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ048 · Cited by 395
Mazuski, J. E., Gasink, L. B., Armstrong, J., Broadhurst, H., Stone, G. G., Rank, D., Llorens, L., Newell, P., & Pachl, J. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw133 · Cited by 393
Wagenlehner, F. M., Umeh, O., Steenbergen, J., Yuan, G., & Darouiche, R. O. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62220-0 · Cited by 388
Babinchak, T., Ellis‐Grosse, E., Dartois, N., Rose, G. M., Loh, E., & Groups, T. 3. A. 3. S. (2005) · Clinical Infectious Diseases · doi:10.1086/431676 · Cited by 381
Falcone, M., Daikos, G. L., Tiseo, G., Bassoulis, D., Giordano, C., Galfo, V., Leonildi, A., Tagliaferri, E., Barnini, S., Sani, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa586 · Cited by 380
Zhanel, G. G., Lawrence, C. K., Adam, H., Schweizer, F., Zelenitsky, S., Zhanel, M., Lagacé-Wiens, P. R. S., Walkty, A., Denisuik, A., Golden, A., et al. (2018) · Drugs · doi:10.1007/s40265-017-0851-9 · Cited by 377
Rodriguez-Bano, J., Navarro, M. D., Retamar, P., Picon, E., Pascual, A., & the Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir790 · Cited by 363
Wagenlehner, F. M., Sobel, J. D., Newell, P., Armstrong, J., Huang, X., Stone, G. G., Yates, K., & Gasink, L. B. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw378 · Cited by 362
Tumbarello, M., Trecarichi, E. M., Corona, A., De Rosa, F. G., Bassetti, M., Mussini, C., Menichetti, F., Viscoli, C., Campoli, C., Venditti, M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy492 · Cited by 354
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-17 · Cited by 353
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
Kollef, M. H., Nováček, M., Kivistik, Ü., Réa-Neto, Á., Shime, N., Martin-Loeches, I., Timsit, J.-F., Wunderink, R. G., Bruno, C. J., Huntington, J. A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30403-7 · Cited by 345
van Duin, D., Arias, C. A., Komarow, L., Chen, L., Hanson, B. M., Weston, G., Cober, E., Garner, O. B., Jacob, J. T., Satlin, M. J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30755-8 · Cited by 337
Self-citationA Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World
Tamma, P. D., Doi, Y., Bonomo, R. A., Johnson, J. K., Simner, P. J., Antibacterial Resistance Leadership Group, Tamma, P. D., Doi, Y., & Bonomo, R. A. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz173 · Cited by 322
Self-citationReyes, J., Komarow, L., Chen, L., Ge, L., Hanson, B. M., Cober, E., Herc, E., Alenazi, T., Kaye, K. S., Garcia-Diaz, J., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00329-9 · Cited by 321
Self-citationBoyd, S. E., Livermore, D. M., Hooper, D. C., & Hope, W. W. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00397-20 · Cited by 315
Tamma, P. D., Han, J. H., Rock, C., Harris, A. D., Lautenbach, E., Hsu, A. J., Avdic, E., & Cosgrove, S. E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ003 · Cited by 314
Self-citationKaye, K. S., Bhowmick, T., Metallidis, S., Bleasdale, S. C., Sagan, O. S., Stus, V., Vazquez, J., Zaitsev, V., Bidair, M., Chorvat, E., et al. (2018) · JAMA · doi:10.1001/jama.2018.0438 · Cited by 314
Falagas, M. E., Rafailidis, P. I., Ioannidou, E., Alexiou, V. G., Matthaiou, D. K., Karageorgopoulos, D. E., Kapaskelis, A., Nikita, D., & Michalopoulos, A. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.005 · Cited by 300
Marshall, S., Hujer, A. M., Rojas, L. J., Papp-Wallace, K. M., Humphries, R. M., Spellberg, B., Hujer, K. M., Marshall, E. K., Rudin, S. D., Perez, F., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02243-16 · Cited by 293
Self-citationPhenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Tamma, P. D., & Simner, P. J. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01140-18 · Cited by 293
Self-citationShields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Kreiswirth, B. N., & Clancy, C. J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02497-17 · Cited by 289
Self-citationComparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia
Freire, A. T., Melnyk, V., Kim, M. J., Datsenko, O., Dzyublik, O., Glumcher, F., Chuang, Y.-C., Maroko, R. T., Dukart, G., Cooper, C. A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.05.012 · Cited by 284
Karakonstantis, S., Rousaki, M., & Kritsotakis, E. I. (2022) · Antibiotics · doi:10.3390/antibiotics11060723 · Cited by 284
Haidar, G., Philips, N. J., Shields, R. K., Snyder, D., Cheng, S., Potoski, B. A., Doi, Y., Hao, B., Press, E. G., Cooper, V. S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix182 · Cited by 277
Self-citationSolomkin, J., Evans, D., Slepavicius, A., Lee, P., Marsh, A., Tsai, L., Sutcliffe, J. A., & Horn, P. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2016.4237 · Cited by 276
Tumbarello, M., Raffaelli, F., Giannella, M., Mantengoli, E., Mularoni, A., Venditti, M., De Rosa, F. G., Sarmati, L., Bassetti, M., Brindicci, G., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab176 · Cited by 275
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes
Bush, K., Macalintal, C., Rasmussen, B. A., Lee, V. J., & Yang, Y. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.4.851 · Cited by 274
Berrazeg, M., Jeannot, K., Ntsogo Enguéné, V. Y., Broutin, I., Loeffert, S., Fournier, D., & Plésiat, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00825-15 · Cited by 268
Efficacy and safety of tigecycline: a systematic review and meta-analysis
Yahav, D., Lador, A., Paul, M., & Leibovici, L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr242 · Cited by 266
Inhibitor-resistant TEM -lactamases: phenotypic, genetic and biochemical characteristics
Chaibi, E. B., Sirot, D., Paul, G., & Labia, R. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.447 · Cited by 256
First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
Humphries, R. M., Yang, S., Hemarajata, P., Ward, K. W., Hindler, J. A., Miller, S. A., & Gregson, A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01165-15 · Cited by 255
Penwell, W. F., Shapiro, A. B., Giacobbe, R. A., Gu, R.-F., Gao, N., Thresher, J., McLaughlin, R. E., Huband, M. D., DeJonge, B. L. M., Ehmann, D. E., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04808-14 · Cited by 251
Satlin, M. J., Lewis, J. S., Weinstein, M. P., Patel, J., Humphries, R. M., Kahlmeter, G., Giske, C. G., & Turnidge, J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa121 · Cited by 250
Cabot, G., Bruchmann, S., Mulet, X., Zamorano, L., Moyà, B., Juan, C., Haussler, S., & Oliver, A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02462-13 · Cited by 247
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014) · Critical Care · doi:10.1186/cc13858 · Cited by 245
Thomson, K. S., & Moland, E. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3548-3554.2001 · Cited by 245
Sirijatuphat, R., & Thamlikitkul, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02435-13 · Cited by 235
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01968-17 · Cited by 235
Systematic Review and Meta-Analysis of In Vitro Synergy of Polymyxins and Carbapenems
Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., Carmeli, Y., & Paul, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01230-13 · Cited by 233
Betrosian, A. P., Frantzeskaki, F., Xanthaki, A., & Douzinas, E. E. (2008) · Journal of Infection · doi:10.1016/j.jinf.2008.04.002 · Cited by 230
Nemec, A. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45716-0 · Cited by 226
Titov, I., Wunderink, R. G., Roquilly, A., Rodríguez Gonzalez, D., David-Wang, A., Boucher, H. W., Kaye, K. S., Losada, M. C., Du, J., Tipping, R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa803 · Cited by 226
AYDEMIR, H., AKDUMAN, D., PISKIN, N., COMERT, F., HORUZ, E., TERZI, A., KOKTURK, F., ORNEK, T., & CELEBI, G. (2013) · Epidemiology and Infection · doi:10.1017/s095026881200194x · Cited by 225
Rojas, L. J., Salim, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Marshall, S., Rudin, S. D., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw805 · Cited by 224
Self-citationMuder, R. R., Harris, A. P., Muller, S., Edmond, M., Chow, J. W., Papadakis, K., Wagener, M. W., Bodey, G. P., & Steckelberg, J. M. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.3.508 · Cited by 223
Safdar, A., & Rolston, K. V. (2007) · Clinical Infectious Diseases · doi:10.1086/522998 · Cited by 223
Solomkin, J. S., Gardovskis, J., Lawrence, K., Montravers, P., Sway, A., Evans, D., & Tsai, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1029 · Cited by 222
Kazmierczak, K. M., Rabine, S., Hackel, M., McLaughlin, R. E., Biedenbach, D. J., Bouchillon, S. K., Sahm, D. F., & Bradford, P. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02379-15 · Cited by 220
Giddins, M. J., Macesic, N., Annavajhala, M. K., Stump, S., Khan, S., McConville, T. H., Mehta, M., Gomez-Simmonds, A., & Uhlemann, A.-C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02101-17 · Cited by 219
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Wagenlehner, F. M. E., Cloutier, D. J., Komirenko, A. S., Cebrik, D. S., Krause, K. M., Keepers, T. R., Connolly, L. E., Miller, L. G., Friedland, I., & Dwyer, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1801467 · Cited by 218
Toleman, M. A., Bennett, P. M., Bennett, D. M. C., Jones, R. N., & Walsh, T. R. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1304.061378 · Cited by 217
Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., Kosiek, K., Martinez de Tejada, B., Roux, X., Shiber, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.3627 · Cited by 214
Boisson, M., Jacobs, M., Grégoire, N., Gobin, P., Marchand, S., Couet, W., & Mimoz, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03510-14 · Cited by 211
Rattanaumpawan, P., Lorsutthitham, J., Ungprasert, P., Angkasekwinai, N., & Thamlikitkul, V. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq360 · Cited by 211
Michalopoulos, A., Kasiakou, S. K., Mastora, Z., Rellos, K., Kapaskelis, A. M., & Falagas, M. E. (2004) · Critical Care · doi:10.1186/cc3020 · Cited by 209
Marchaim, D., Chopra, T., Pogue, J. M., Perez, F., Hujer, A. M., Rudin, S., Endimiani, A., Navon-Venezia, S., Hothi, J., Slim, J., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01020-10 · Cited by 208
Self-citationAlonso, A., & Martínez, J. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3079-3086.2000 · Cited by 207
Lu, Q., Luo, R., Bodin, L., Yang, J., Zahr, N., Aubry, A., Golmard, J.-L., & Rouby, J.-J. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31827515de · Cited by 207
Kofteridis, D. P., Alexopoulou, C., Valachis, A., Maraki, S., Dimopoulou, D., Georgopoulos, D., & Samonis, G. (2010) · Clinical Infectious Diseases · doi:10.1086/657242 · Cited by 207
Fraile-Ribot, P. A., Cabot, G., Mulet, X., Periañez, L., Martín-Pena, M. L., Juan, C., Pérez, J. L., & Oliver, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx424 · Cited by 207
Pogue, J. M., Kaye, K. S., Veve, M. P., Patel, T. S., Gerlach, A. T., Davis, S. L., Puzniak, L. A., File, T. M., Olson, S., Dhar, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz816 · Cited by 206
Self-citationAkajagbor, D. S., Wilson, S. L., Shere-Wolfe, K. D., Dakum, P., Charurat, M. E., & Gilliam, B. L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit453 · Cited by 205
Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene
Ito, R., Mustapha, M. M., Tomich, A. D., Callaghan, J. D., McElheny, C. L., Mettus, R. T., Shanks, R. M. Q., Sluis-Cremer, N., & Doi, Y. (2017) · mBio · doi:10.1128/mbio.00749-17 · Cited by 204
Mauri, C., Maraolo, A. E., Di Bella, S., Luzzaro, F., & Principe, L. (2021) · Antibiotics · doi:10.3390/antibiotics10081012 · Cited by 203
Hackel, M. A., Tsuji, M., Yamano, Y., Echols, R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00093-17 · Cited by 202
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China
Zhang, P., Shi, Q., Hu, H., Hong, B., Wu, X., Du, X., Akova, M., & Yu, Y. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.08.020 · Cited by 200
Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem
Kuti, J. L., Dandekar, P. K., Nightingale, C. H., & Nicolau, D. P. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003257225 · Cited by 199
Karlowsky, J. A., Kazmierczak, K. M., de Jonge, B. L. M., Hackel, M. A., Sahm, D. F., & Bradford, P. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00472-17 · Cited by 194
Kazmierczak, K. M., Tsuji, M., Wise, M. G., Hackel, M., Yamano, Y., Echols, R., & Sahm, D. F. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.10.007 · Cited by 193
Short-Course Nitrofurantoin for the Treatment of Acute Uncomplicated Cystitis in Women
Gupta, K. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.20.2207 · Cited by 192
Ito, A., Kohira, N., Bouchillon, S. K., West, J., Rittenhouse, S., Sader, H. S., Rhomberg, P. R., Jones, R. N., Yoshizawa, H., Nakamura, R., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv402 · Cited by 192
Michalopoulos, A., Fotakis, D., Virtzili, S., Vletsas, C., Raftopoulou, S., Mastora, Z., & Falagas, M. E. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2007.10.011 · Cited by 191
Kwa, A. L. H., Loh, C., Low, J. G. H., Kurup, A., & Tam, V. H. (2005) · Clinical Infectious Diseases · doi:10.1086/432583 · Cited by 191
Yamano, Y. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz827 · Cited by 191
Choi, S.-H., Lee, J. E., Park, S. J., Choi, S.-H., Lee, S.-O., Jeong, J.-Y., Kim, M.-N., Woo, J. H., & Kim, Y. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01083-07 · Cited by 190
Zhang, L., Li, X.-Z., & Poole, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.287-293.2000 · Cited by 190
Polymyxin B: similarities to and differences from colistin (polymyxin E)
Kwa, A., Kasiakou, S. K., Tam, V. H., & Falagas, M. E. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.811 · Cited by 190
Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.-A., Bille, J., Aymon, D., Stratchounski, L., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3442-3447.2003 · Cited by 190
Falcone, M., Tiseo, G., Leonildi, A., Della Sala, L., Vecchione, A., Barnini, S., Farcomeni, A., & Menichetti, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02142-21 · Cited by 190
Sandberg, T., Skoog, G., Hermansson, A. B., Kahlmeter, G., Kuylenstierna, N., Lannergård, A., Otto, G., Settergren, B., & Ekman, G. S. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60608-4 · Cited by 189
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Tamma, P. D., & Rodriguez-Baňo, J. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix034 · Cited by 186
Self-citationHooton, T. M., Scholes, D., Gupta, K., Stapleton, A. E., Roberts, P. L., & Stamm, W. E. (2005) · JAMA · doi:10.1001/jama.293.8.949 · Cited by 185
Regulatory components in Citrobacter freundii ampC beta-lactamase induction.
Lindberg, F., Westman, L., & Normark, S. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.14.4620 · Cited by 182
Batirel, A., Balkan, I. I., Karabay, O., Agalar, C., Akalin, S., Alici, O., Alp, E., Altay, F. A., Altin, N., Arslan, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2070-6 · Cited by 182
Tumbarello, M., De Pascale, G., Trecarichi, E. M., De Martino, S., Bello, G., Maviglia, R., Spanu, T., & Antonelli, M. (2013) · Chest · doi:10.1378/chest.13-1018 · Cited by 182
Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M., Rizk, M. L., Brown, M. L., Losada, M. C., Pedley, A., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00633-16 · Cited by 182
Risk Factors for Emergence of Resistance to Broad-Spectrum Cephalosporins among Enterobacter spp
Kaye, K. S., Cosgrove, S., Harris, A., Eliopoulos, G. M., & Carmeli, Y. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2628-2630.2001 · Cited by 181
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., & Quale, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00830-15 · Cited by 181
Falagas, M. E., Valkimadi, P.-E., Huang, Y.-T., Matthaiou, D. K., & Hsueh, P.-R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn301 · Cited by 181
Honoré, N., Nicolas, M. H., & Cole, S. T. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04704.x · Cited by 180
Phe, K., Lee, Y., McDaneld, P. M., Prasad, N., Yin, T., Figueroa, D. A., Musick, W. L., Cottreau, J. M., Hu, M., & Tam, V. H. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02476-13 · Cited by 180
Falagas, M. E., Kastoris, A. C., Vouloumanou, E. K., Rafailidis, P. I., Kapaskelis, A. M., & Dimopoulos, G. (2009) · Future Microbiology · doi:10.2217/fmb.09.84 · Cited by 179
Castanheira, M., Farrell, S. E., Krause, K. M., Jones, R. N., & Sader, H. S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01896-13 · Cited by 177
Bacteremia Due to Stenotrophomonas maltophilia in Patients with Hematologic Malignancies
Micozzi, A., Venditti, M., Monaco, M., Friedrich, A., Taglietti, F., Santilli, S., & Martino, P. (2000) · Clinical Infectious Diseases · doi:10.1086/314043 · Cited by 176
Lee, N.-Y., Lee, C.-C., Huang, W.-H., Tsui, K.-C., Hsueh, P.-R., & Ko, W.-C. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cis916 · Cited by 175
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
Kaye, K. S., Marchaim, D., Thamlikitkul, V., Carmeli, Y., Chiu, C., Daikos, G. L., Dhar, S., Durante‐Mangoni, E., Gikas, A. I., Kotanidou, A. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200131 · Cited by 175
Kollef, M. H., Ricard, J.-D., Roux, D., Francois, B., Ischaki, E., Rozgonyi, Z., Boulain, T., Ivanyi, Z., János, G., Garot, D., et al. (2017) · Chest · doi:10.1016/j.chest.2016.11.026 · Cited by 173
The Use of Cefepime for Treating AmpC β-Lactamase–Producing Enterobacteriaceae
Tamma, P. D., Girdwood, S. C. T., Gopaul, R., Tekle, T., Roberts, A. A., Harris, A. D., Cosgrove, S. E., & Carroll, K. C. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit395 · Cited by 172
Self-citationPopulation Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients
Li, C., Kuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291035 · Cited by 171
Lesho, E., Yoon, E.-J., McGann, P., Snesrud, E., Kwak, Y., Milillo, M., Onmus-Leone, F., Preston, L., St. Clair, K., Nikolich, M., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit293 · Cited by 171
Korbila, I. P., Michalopoulos, A., Rafailidis, P. I., Nikita, D., Samonis, G., & Falagas, M. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03040.x · Cited by 170
Ackley, R., Roshdy, D., Meredith, J., Minor, S., Anderson, W. E., Capraro, G. A., & Polk, C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02313-19 · Cited by 170
Gutiérrez‐Gutiérrez, B., Pérez-Galera, S. I., Salamanca, E., de Cueto, M., Calbo, E., Almirante, B., Viale, P., Oliver, A., Pintado, V., Gasch, O., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00365-16 · Cited by 167
Self-citationRello, J., Solé-Lleonart, C., Rouby, J.-J., Chastre, J., Blot, S., Poulakou, G., Luyt, C.-E., Riera, J., Palmer, L. B., Pereira, J. M., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.04.011 · Cited by 167
Livermore, D. M., Warner, M., Jamrozy, D., Mushtaq, S., Nichols, W. W., Mustafa, N., & Woodford, N. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00678-15 · Cited by 166
Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y.-C., Brown, M. L., Du, J., Pedley, A., Kartsonis, N. A., & Paschke, A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx139 · Cited by 166
Sun, D., Rubio-Aparicio, D., Nelson, K., Dudley, M. N., & Lomovskaya, O. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01694-17 · Cited by 166
Jacobson, K. L., Cohen, S. H., Inciardi, J. F., King, J. H., Lippert, W. E., Iglesias, T., & VanCouwenberghe, C. J. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.5.1107 · Cited by 165
Motaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., Belabbes, H., & Benbachir, M. (2006) · Journal of Infection · doi:10.1016/j.jinf.2005.11.019 · Cited by 165
New Perspectives on Antimicrobial Agents: Cefiderocol
McCreary, E. K., Heil, E. L., & Tamma, P. D. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02171-20 · Cited by 165
Self-citationNichols, W. W., de Jonge, B. L. M., Kazmierczak, K. M., Karlowsky, J. A., & Sahm, D. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00220-16 · Cited by 163
OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline
Boyd, S. E., Holmes, A., Peck, R., Livermore, D. M., & Hope, W. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00216-22 · Cited by 163
de Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03042-15 · Cited by 162
Henderson, A., Paterson, D. L., Chatfield, M. D., Tambyah, P. A., Lye, D. C., De, P. P., Lin, R. T. P., Chew, K. L., Yin, M., Lee, T. H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1479 · Cited by 161
Tamma, P. D., Conley, A. T., Cosgrove, S. E., Harris, A. D., Lautenbach, E., Amoah, J., Avdic, E., Tolomeo, P., Wise, J., Subudhi, S., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.6226 · Cited by 160
Self-citationShaw, E., Rombauts, A., Tubau, F., Padullés, A., Càmara, J., Lozano, T., Cobo-Sacristán, S., Sabe, N., Grau, I., Rigo-Bonnin, R., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx496 · Cited by 159
Clinical challenges treating Stenotrophomonas maltophilia infections: an update
Mojica, M. F., Humphries, R., Lipuma, J. J., Mathers, A. J., Rao, G. G., Shelburne, S. A., Fouts, D. E., Van Duin, D., & Bonomo, R. A. (2022) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlac040 · Cited by 159
Self-citationMontero, A., Ariza, J., Corbella, X., Doménech, A., Cabellos, C., Ayats, J., Tubau, F., Borraz, C., & Gudiol, F. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh485 · Cited by 158
Gröschel, M. I., Meehan, C. J., Barilar, I., Diricks, M., Gonzaga, A., Steglich, M., Conchillo‐Solé, O., Scherer, I.-C., Mamat, U., Luz, C. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15123-0 · Cited by 158
Liu, J., Shu, Y., Zhu, F., Feng, B., Zhang, Z., Liu, L., & Wang, G. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.08.021 · Cited by 157
Use of colistin in the treatment of multiple-drug-resistant gram-negative infections
Berlana, D., Llop, J. M., Casamartina, E. F., Badia, M., & Jódar, R. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.1.39 · Cited by 155
Castón, J. J., Lacort-Peralta, I., Martín‐Dávila, P., Loeches, B., Tabares, S., Temkin, L., Torre‐Cisneros, J., & Paño‐Pardo, J. R. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.03.021 · Cited by 154
Livermore, D. M., Mushtaq, S., Warner, M., & Woodford, N. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00436-16 · Cited by 152
Montero, A., Ariza, J., Corbella, X., Domenech, A., Cabellos, C., Ayats, J., Tubau, F., Ardanuy, C., & Gudiol, F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1946-1952.2002 · Cited by 151
Inhaled Antibiotics for Gram-Negative Respiratory Infections
Wenzler, E., Fraidenburg, D. R., Scardina, T. L., & Danziger, L. H. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00101-15 · Cited by 151
The epidemiology of carbapenemases in Latin America and the Caribbean
Escandón-Vargas, K., Reyes, S., Gutiérrez, S., & Villegas, M. V. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268918 · Cited by 151
Dobias, J., Tendon, V. D., Poirel, L., & Nordmann, P. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3063-z · Cited by 151
Tuon, F. F., Rigatto, M. H., Lopes, C. K., Kamei, L. K., Rocha, J. L. L., & Zavascki, A. P. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.12.002 · Cited by 150
Jaruratanasirikul, S., Sriwiriyajan, S., & Punyo, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1337-1339.2005 · Cited by 149
Karlowsky, J. A., Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.007 · Cited by 149
Livermore, D. M., Andrews, J. M., Hawkey, P. M., Ho, P., Keness, Y., Doi, Y., Paterson, D. L., & Woodford, N. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks088 · Cited by 148
Abdellatif, S., Trifi, A., Daly, F., Mahjoub, K., Nasri, R., & Lakhal, S. B. (2016) · Annals of Intensive Care · doi:10.1186/s13613-016-0127-7 · Cited by 148
Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Quale, J. M., & Landman, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00843-15 · Cited by 147
Páez, J. I. G., & Costa, S. F. (2008) · Journal of Hospital Infection · doi:10.1016/j.jhin.2008.05.020 · Cited by 146
Rigatto, M. H., de Oliveira, M. S., Neto, L. V. P., Levin, A. S., Carrilho, C. M. D. D. M., Tanita, M. T., Tuon, F. F., Cardoso, D. E., Lopes, N. T., Falci, D. R., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02634-15 · Cited by 145
Rifamycins, Alone and in CombinationPreprint
Rothstein, D. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027011 · Cited by 145
Shields, R. K., Clancy, C. J., Gillis, L. M., Kwak, E. J., Silveira, F. P., Abdel-Massih, R. C., Eschenauer, G. A., Potoski, B. A., & Nguyen, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052349 · Cited by 144
Self-citationAbdallah, M., Olafisoye, O., Cortes, C. D., Urban, C. M., Landman, D., & Quale, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04809-14 · Cited by 144
Landersdorfer, C. B., Wang, J., Wirth, V., Chen, K., Kaye, K. S., Tsuji, B. T., Li, J., & Nation, R. L. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx409 · Cited by 143
Haidar, G., Clancy, C. J., Chen, L., Samanta, P., Shields, R. K., Kreiswirth, B. N., & Nguyen, M. H. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00642-17 · Cited by 142
Self-citationCastanheira, M., Mills, J. C., Farrell, D. J., & Jones, R. N. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03681-14 · Cited by 141
Sader, H. S., Huband, M. D., Castanheira, M., & Flamm, R. K. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02252-16 · Cited by 141
Winkler, M., Papp‐Wallace, K. M., & Bonomo, R. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv094 · Cited by 140
Self-citationNg, T. M., Khong, W. X. L., Harris, P. N. A., De, P. P., Chow, A. L., Tambyah, P. A., & Lye, D. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153696 · Cited by 140
Lob, S. H., Hackel, M., Kazmierczak, K. M., Young, K., Motyl, M. R., Karlowsky, J. A., & Sahm, D. F. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02209-16 · Cited by 140
Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity
Nation, R. L., Rigatto, M. H., Falci, D. R., & Zavascki, A. P. (2019) · Antibiotics · doi:10.3390/antibiotics8010024 · Cited by 140
Niederman, M. S., Alder, J. D., Bassetti, M., Boateng, F., Cao, B., Corkery, K. J., Dhand, R., Kaye, K. S., Lawatscheck, R., McLeroth, P., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30574-2 · Cited by 140
Betrosian, A. P., Frantzeskaki, F. G., Xanthaki, A., & Georgiadis, G. (2007) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540600951184 · Cited by 138
Falcone, M., Tiseo, G., Nicastro, M., Leonildi, A., Vecchione, A., Casella, C., Forfori, F., Malacarne, P., Guarracino, F., Barnini, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1410 · Cited by 138
Emeraud, C., Escaut, L., Boucly, A., Fortineau, N., Bonnin, R. A., Naas, T., & Dortet, L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00010-19 · Cited by 136
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
“…(for which sulbactam is the active component against A. baumannii PBP3) is the current preferred backbone of therapy, with evidence of improved outcomes when used at a high dose (≥9 g per day of sulbactam) in combination with another active agent in mostly observational studies 180 .”
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat
Lei, T.-Y., Liao, B.-B., Yang, L.-R., Wang, Y., & Chen, X.-B. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127839 · Cited by 174
Kaye, K. S., Belley, A. C., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Vélicitat, P. (2022) · JAMA · doi:10.1001/jama.2022.17034 · Cited by 147
Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre‐Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., Zhao, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00499-7 · Cited by 146
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.